Characterization of canine mastocytoma cell response to cryoablation

Kimberly L Santucci1, Kristi K Snyder1, Robert G Van Buskirk1-3, John G Baust2,3 and John M Baust1*

1CPSI Biotech, Owego, NY, USA
2Center for Translational Stem Cell and Tissue Engineering Binghamton University, 4400 Vestal Parkway East, Binghamton, NY 13902, USA
3Department of Biological Sciences, Binghamton University, 4400 Vestal Parkway East, Binghamton, NY 13902, USA

Abstract

Introduction: Mastocytoma Tumors (MCT) represent 16%-21% of all skin cancers in dogs, making it the most common form of cutaneous cancer. Solitary MCT are typically treated with wide surgical excision margins. While effective, MCT excision can cause the release of a large amount of histamine and other cytokines resulting in complications such as systemic shock or anaphylaxis. Treatments such as chemotherapy and radiotherapy have been considered to achieve complete remission. Cryoablation also represents a potential treatment option for MCT. While studies have shown cryoablation to be beneficial for the treatment of numerous cancers in animals and humans, few studies have described the use of cryoablation to treat MCT's. The limited use of cryoablation is due to a number of factors including a lack of basic information pertaining to dosing (minimal lethal temperature) necessary to destroy MCT cancer. As such, in this study we conducted a series of in vitro studies using the C2 cell line and a pilot ex vivo fine needle aspirate tissue sample in an effort to detail the effects of freezing of canine MCT.

Methods: Samples were exposed to temperatures ranging from -5°C to -25°C, modeling the periphery of a cryogenic lesion for 3, 5 and 10minutes, and various markers of viability and modes of cell death were assessed daily over a 3 days recovery period. Additionally, investigation of the involvement of apoptosis in MCT cell death following freezing was conducted via immunoblotting and caspase inhibition studies.

Results: Viability studies revealed the -25°C isotherm as the critical minimal lethal temperature to achieve complete MCT cell death regardless of hold time. As the hold time at temperatures of -15°C and -20°C increased from 3 to 10minutes the level of cell death was also found to increase. Fluorescence microscopy, caspase inhibition and protein analysis revealed necrosis to be the primary mode of cell death following freezing. These studies, however, also revealed a significant level of apoptotic cell death post-freeze. Molecular analysis suggested that freezing to -15°C to -20°C resulted in the activation of mitochondrial mediated apoptosis 4 to 8 hours post freeze.

Conclusions: In summary, this in vitro study was designed as a first step investigation into the sensitivity of MCT cancer to freezing. These in vitro results suggest that freezing to temperatures of ≤-20°C results in a high degree of MCT cell destruction. Further the data suggest that both apoptosis and necrosis play an important role in cell death following cryoablation. These data may have translational application to MCT treatment in vivo.
Cryoablation (CA) is the use of ultra-low temperatures to provide targeted freezing and subsequent destruction of cancerous or non-cancerous tissues. As a minimally invasive modality with less side effects than radiation and chemotherapy, CA is an attractive option for the treatment of solid tumors [11-13]. Cryosurgical techniques include ultrasound guided imaging to visualize ice ball formation as well as temperature monitoring by the placement of multiple thermocouples [13-15]. CA has been applied with a high degree of success in the treatment of skin, prostate, renal, liver, breast, and bone cancers, among others in both humans and animals [16-23]. To this end, several reports have demonstrated CA as effective or superior to other cancer treatment options including surgery, radiotherapy and chemotherapy [12,24-26]. In addition to being an effective cancer therapy, CA has the benefit of low incidence of postoperative morbidity, low levels of pain, and is often utilized as a outpatient surgical approach [12,24,25]. CA also offers the benefit of being a minimally invasive procedure thereby reducing and in some cases eliminating the need for general anesthesia [13,14].

Cryosurgery also has a long but limited history of application in the veterinary setting. Some of the first reports of CA in small animals were in the treatment of dermatological conditions in dogs and cats [27-29]. Over time, the range of CA treated neoplasms has expanded to include less accessible organs. CA has been reported in numerous cases as early as 1971 for the treatment of laryngeal neoplasms [30-32]. Additionally, cardiac CA procedures have been performed to treat canine arrhythmias [33], as well as to test the feasibility of epicardial ablation [34]. One study performed on canine renal neoplasms determined the procedure was a safe and feasible treatment option [35] and a case report described successful CA of a canine intranasal tumor [36]. These studies illustrate the use of cryosurgery as a possible treatment option for a variety of disease states.

The reported benefits and effectiveness of CA in both the veterinary and human cancer therapy arenas suggests that CA may represent a viable option for MCT. While a potential option, there is little information in the primary literature as to the effectiveness and response of MCT’s to CA. Numerous studies have detailed the effects of freezing in various cell systems demonstrating a differential response to similar freezing insults. Cell death due to freezing is not only a consequence of freeze rupture, but is also related to differential freeze–induced cell stress response which is believed to dictate therapeutic outcome [15,26,37]. Studies have also demonstrated that different molecular dispositions (sub-types) of the same cancer tissue type can respond differently to CA [38-40]. We have published studies using numerous cell models investigating this phenomenon [12,26,40]. For instance, Snyder, et al., have shown that breast cancer cells tolerate freezing to −15°C, whereas cardiac cells can withstand −30°C [41,42]. Other studies have demonstrated prostate cancer cells tolerate −40°C to −80°C [12,43,44]. Studies have also established the translatable of in vitro data to clinical outcome and protocol establishment. For example, in vitro studies by Gage, et al., [12,13,45], led to the clinical target of −40°C for prostate cancer. Studies by Snyder, et al., [41] and others [46], established −30°C as the target for cardiac ablation. More recently, in vitro cell and tissue engineered model studies proved critical to the development of the percutaneous SCN system for prostate cancer [47,48]. Given the potential of CA, we conducted a series of cellular and molecular based analyses of mast cells following exposure to sub-freezing temperatures using the C2 cell line in order to gain an understanding of MCT cell response to CA. The C2 mast cell line was derived from a canine with end-stage illness after multiple metastases were observed and thereby represents an aggressive and advanced form of MCT cancer [49]. The temperature range of −5°C to −25°C was selected for investigation as it represents the reported transitional temperature range between complete cell death and survival in a number of cancers [11,13,15,50,51]. We hypothesized that delivery of an effective freeze dose (temperature and time) would result in complete C2 cell destruction. Further, we hypothesized that both apoptotic and necrotic pathways are activated following exposure to mild sub–freezing temperatures and that this molecular signaling plays a critical role in the extent of cell death.

Materials and methods

Cell culture

The C2 canine mastocytoma cell line was obtained from Dr. J. Wakshlag (Cornell University, Ithaca, NY, USA). Cultures were maintained in Falcon T-75 flasks at 37°C/ 5% CO₂ in complete media (RPMI-1640 (Caisson Labs, North Logan, UT, USA) with 10% fetal bovine serum (Caisson Labs), 1% penicillin/ streptomycin (Cristech Labs, North Logan, UT, USA), 1% sodium pyruvate (Lonza, Walkersville, MD, USA), and 0.5% 2-ME (60μM final concentration) (Sigma-Aldrich, St. Louis, MO, USA)), exchanged every 2 days. Experimental subcultures were plated into 96 well strip well plates (Costar strips (Corning) with 75μl medium per well or 35mm Costar strips (Corning) with 75μl medium per well or 35mm
Falcon dishes with 1.5ml medium per dish were placed on a pre-cooled block within a circulating temperature-controlled bath at a preset temperature. Samples were frozen to temperatures of -5, -10, -15, -20 or -25°C. Sample temperature was monitored with a type T thermocouple (Omega, Stamford, CT, USA) and ice nucleation was initiated by liquid nitrogen vapor (crystallized water vapor) when samples reached -2°C (±1°C). Samples were held for 3, 5, or 10min and then allowed to thaw at room temperature (10min) before return to normothermic culture (37°C) to allow for system recovery and downstream assessment.

**Cell viability**

Sample viability was assessed post-thaw using the metabolic activity assay alamarBlue (Invitrogen, Carlsbad, CA, USA), diluted 1:20 in Hanks balanced salt solution (Mediatech). Media was aspirated and replaced with 100μl per well alamarBlue for 1h incubation at 37°C, and subsequently analyzed with a Tecan SPECTRAFluorPlus plate reader (TECAN Austria GmbH, Grödig, Austria) at excitation λ=530nm and emission λ=590nm. Following assessment, fresh media was replaced and samples were returned to 37°C. Assessment was repeated daily over a 3 days recovery period.

**Caspase inhibition assay**

Pan caspase inhibitor VI (EMD Millipore, Billerica, MA, USA) was reconstituted in dimethyl sulfoxide at a concentration of 10mM and diluted to a final concentration of 10μl in culture media prior to use. Inhibitor was applied in fresh medium to C2 subcultures in costar plates and kept at 37°C for 30minutes prior to freeze exposure.

**Fluorescence microscopy**

Samples were frozen as described and then fluorescence imaging was conducted at 1, 4, 8 and 24h post-freeze. Prior to imaging, samples were labeled with tri-stain fluorescent probes Hoechst (living cells, 0.06μg/μl), propidium iodide (necrotic cells, 0.007μg/μl), and YO-PRO-1 (apoptotic cells, 0.8μM) (Molecular Probes, Invitrogen, Eugene, OR, USA) to allow for identification of living, necrotic, and apoptotic populations within the sample. Samples were incubated for 15min in the dark before visualization using Zeiss Axiosvert software (Carl Zeiss Microimaging, Thornwood, NY, USA) at 20×magnification.

**Immunoblotting**

Total protein was isolated temporally at 1, 4, 8 and 24hours post-freeze using radioimmunoprecipitation assay (RIPA) buffer with Halt protease inhibitor cocktail (Thermo Scientific, Rockford, IL, USA). Cell lysates were centrifuged for 15minutes at 13,000 rpm to collect the supernatant protein. Protein levels were quantified using a bicinchoninic acid protein assay kit (Pierce, Thermo Scientific). Equal amounts of protein (45μg) were separated on 12% polyacrylamide gels for 50min at 200 V and then transferred to polyvinylidene difluoride membranes using a semi-dry transfer system (Bio-Rad, Hercules, CA, USA) for 30min at 15V. Membranes were blocked with a non-animal protein buffer (G-Biosciences, Maryland Heights, MO, USA) diluted 1:1 with Tris-buffered saline and 0.1% Tween-20 for 1h at room temperature. Membranes were exposed to primary antibody overnight at 4°C in a humidiy chamber. Primary antibodies were validated by the manufacturer for canine reactivity and include: phospho-Akt (1:500, Cell Signaling Technology, Danvers, MA, USA); Bel2 (1:250, BD Transduction Laboratories, Franklin Lakes, NJ, USA); PARP (1:500, BD), Bax (1:500, BD), and α-tubulin (1:2000, abcam, Cambridge, MA, USA). Antibodies were diluted in a 1:2 solution of non-animal protein buffer and Tris-buffered saline with 0.1% Tween-20. Membranes were then washed (three washes at ten minutes each with agitation) in Tris-buffered saline with 0.1% Tween-20 prior to 1h room temperature secondary antibody hybridization in a 1:2 dilution of non-animal protein buffer in Tris-buffered saline with 0.1% Tween-20 with goat anti-rabbit–HRP (1:10,000, Pierce) or goat anti-mouse–HRP (1:10,000, Pierce) and StrepTactin–HRP (1:40,000, Bio-Rad) for molecular weight marker visualization. Membranes were then washed as described above before detection using the LumiGLO/Peroxidase chemiluminescent detection kit (CST) on a FujiFilm LAS-3000 system (FujiFilm, Edison, NJ, USA). Molecular weight was confirmed by migration of the western C–HRP protein marker (Bio–Rad).

**Freezing of mast cell tumor tissue**

A primary canine mast cell tumor biopsy was obtained via a fine needle aspirate procedure (Dr. A. Beaulieu, DVM, Dickin Memorial Animal Hospital, Johnson City, NY, USA). Following harvest, the biopsy was immediately placed in Viaspan and held at 4°C for 24h. Prior to experimentation, tissue was rinsed with a 1×phosphate-buffered saline (PBS, Mediatech) solution, sectioned and weighed. The control section was cultured with C2 complete media at 37°C. The experimental tissue samples were placed into a thin–walled PCR tube with 500μl media and then subjected to a short (2m30s) freeze exposure to -20°C (±1°C). Temperature was monitored with a type T thermocouple (Omega, Stamford, CT, USA) placed in the center of a representative the tissue sample. Following freeze exposure, the samples were placed into ex vivo tissue culture and assessed for viability at 1 and 24h post freeze. To assess viability, 1mL alamarBlue diluted 1:20 in HBSS was placed on each tissue section for 1h; the alamarBlue solution was aspirated into wells of a 96–well plate for spectrophotometer analysis and the tissue samples were returned to culture with fresh medium. Fluorescent units were then compared to non-treated tissue samples to determine percent viability.

**Data analysis**

Experiments were repeated a minimum of three times with an intra-experimental replicate of 7 samples/condition. Statistical significance (p<0.01) was determined by one way ANOVA using Excel. Viability is expressed as percent of control. Calculations of standard error mean (±SEM) was conducted using the 2t wells from combined experiments. Immunoblot protein bands were quantified with background values subtracted using densitometric analysis on Fuji Film Multi Gauge software V2.3 (Fuji Film).
Results

Impact of temperature and hold time on C2 survival

The C2 canine mastocytoma cell line was exposed to temperatures ranging from -5°C to -25°C and cell viability was assessed at 24h post-thaw (Figure 1). Regardless of exposure time (3, 5, or 10minutes), samples exposed to -5°C and -10°C demonstrated no significant cell loss compared to controls (p>0.05). Exposure to temperatures of -15°C and -20°C resulted in complete cell death regardless of the hold time. These data indicated that exposure time is a significant factor in C2 cell ablation at temperatures between -15°C and -20°C. The analysis confirmed the relative level of cell death (apoptosis and necrosis) and viability at 24h within each population as was found in the viability studies (Figure 2). Analysis at 1h following a -10°C freeze revealed an increase in the levels of apoptosis/necrosis following exposure to -20°C (5-12%), no re-growth was noted in any of the -20°C samples over the 3 day recovery period. Exposure to -25°C resulted in complete cell death regardless of the hold time. These data indicated that exposure time is a factor in C2 cell ablation at temperatures between -15°C and -20°C. However, when exposed to temperatures of ≤-25°C, complete ablation was achieved regardless of the exposure time.

Fluorescence microscopy correlates apoptosis and necrosis post-freeze

To visually assess the temporal regulation of cell death, fluorescence microscopy analysis was conducted using probes specific for apoptosis (YO-Pro-1) or necrosis (Propidium Iodide (PI)) at 1, 4, 8, and 24h post-thaw following exposure to -10°C, -15°C, and -20°C. The analysis confirmed the relative level of cell death (apoptosis and necrosis) and viability at 24h within each population as was found in the viability studies (Figure 2). Analysis at 1h following a -10°C freeze revealed an increase in the levels of apoptosis/necrosis over that of untreated controls. Continued presence of apoptotic and necrotic populations was observed 4h and 8h post-freeze. Yet by 24h post-freeze, -10°C samples did not differ significantly from controls. Following freezing to -15°C a significant population of apoptotic and necrotic cells were apparent as early as 1h post-freeze. A continued increase in both populations was observed at 4h and 8h post-freeze resulting in a significant decline in viability at 24h post-freeze. Samples exposed to -20°C also revealed an even greater level of positive staining for apoptosis and necrosis at 1, 4 and 8hours post-freeze resulting in ≤10% survival at 24hours, which was consistent with the metabolic activity assessment. Interestingly, the levels of cell death were found to peak at 8 hours post-thaw in both the -20°C and -15°C samples illustrating the involvement of a delayed cell death response.

Molecular analysis of relevant proteins

With the identification of a delayed cell death response (apoptotic and necrotic activity) via fluorescence microscopy, temporal (1, 4, 8 and 24hours) analysis of cell stress protein levels following freezing at -10°C and -15°C was conducted via western blotting (Figure 3). Protein analyses revealed reductions in the anti-apoptotic protein Bcl-2 levels following freezing when compared to controls. The greatest decrease in Bcl-2 levels was seen within 1hour following freezing to -10°C and -15°C and continued throughout the 24h assessment period. Freezing to -20°C yielded almost exclusively necrotic death.

Following exposure to −15°C. Compared to controls, pAKT levels −10°C samples were reduced by two fold at 1h post-freeze. This reduction increased to 4.5 fold at 4h, and 13.7 fold at 8h post-freeze. By 24h post freeze, pAKT protein levels began to recover yielding levels similar to the 4h post freeze sample. Analysis of −15°C samples revealed virtually no phosphorylated Akt at any time point assessed. This may indicate that freeze stress may prevent the initiation of survival signaling via AKT, thereby augmenting cell death. Western blot analysis of PARP (poly-ADP ribose polymerase), a protein activated during DNA repair and one of the first targets of the apoptotic “executioner” enzyme caspase−3, revealed proteolytic cleavage products at 4, and 8 hours following a −10°C freeze. PARP analysis from −15°C samples revealed an increase in cleavage products at 4 and 8 hours compared to −10°C samples and complete degradation of PARP cleavage products by 24 hours. Comparing −10°C and −15°C samples, PARP cleavage was found to be greater and quicker in the −15°C samples peaking at 4 hours whereas −10°C samples peaked at 8 hours post-thaw (Table 1).

**Inhibition of caspasases decreases the contribution of apoptotic cell death processes post-freeze**

With the identification of a delayed cell death and alterations in apoptosis related proteins following freezing, assessment of the impact of caspase inhibition on cell survival following freezing was conducted. This analysis was performed as a first step in quantifying the level of apoptotic involvement in cell death following freezing. C2 cells were pre-treated with a pan caspase inhibitor for 30 minutes prior to freeze to −10°C, −15°C and −20°C. As with freezing only samples, exposure to −10°C in the presence of caspase inhibitors did not significantly impact cell viability (Figure 4). Exposure to −15°C in the presence of caspase inhibition resulted in a 13.6% improvement in overall survival (26.6% increase) compared to non-inhibited −15°C samples (64.42% (±1.6) vs. 50.84% (±1.7), p<0.001 (Figure 4)). These results indicated that the apoptotic caspases signaling contributed to cell death following a −15°C freeze. When samples were exposed to −20°C in the presence of caspase inhibition no significant change in cell survival was noted.

**Primary mast cell tumor isolate response to low temperature exposure**

In addition to the *in vitro* C2 studies, analysis of a primary grade 2, stage 2 canine MCT tumor sample was conducted. The MCT sample was excised via fine needle aspirate biopsy procedure, sectioned, weighed and then exposed to −20°C (Figure 5A). Following freezing, tissue sections were placed into *ex vivo* culture and analyzed for tissue viability at 1 and 24h post-thaw (Figure 5B). The response of the tissue samples was found to be similar to the C2 in *vitro* results. Tissue sample viability at 1 hour post-thaw was found to be 40% of non-frozen controls. Following 24h of recovery, a further decrease in viability to 12% was observed. While a pilot *ex vivo* case study, the experimental results were found to correlate well with the *in vitro* freeze response data obtained with the C2 cell model following exposure to −20°C for 3 minutes.

**Discussion**

CA is an effective cancer treatment modality. However, the application of CA in veterinary medicine has been limited. In this study we investigated the effects of CA on MCT cells in an attempt to characterize MCT cell response to freezing, as well as identify the critical target temperature necessary to achieve total cell destruction. The data from this study demonstrated that CA was effective at destroying MCT cells when temperatures...

**Table 1:** Densitometric analysis of immunoblots. Values were obtained using Fuji Film Multi Gauge software V2.3. Background values were subtracted from each band prior to comparative analysis.

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>−10°C</th>
<th>−15°C</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phospho Akt</td>
<td>22.5</td>
<td>28.5</td>
<td>29.3</td>
</tr>
<tr>
<td>Bcl2</td>
<td>11.6</td>
<td>12.2</td>
<td>13.5</td>
</tr>
<tr>
<td>Parp full</td>
<td>15.1</td>
<td>21.1</td>
<td>15.3</td>
</tr>
<tr>
<td>Parp Cleaved</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

**Figure 3:** Immunoblot analysis of cellular proteins following freezing to −10°C or −15°C. Samples were evaluated for alterations in phospho-Akt, Bcl-2, PARP and α-tubulin (loading control) temporally following freezing. A decrease in phosphorylated Akt (pAKT) was observed following freezing to −10°C and was found to be even greater following exposure to −15°C. Alterations in Bcl-2 and PARP (poly-ADP ribose) protein levels were also observed at 4 and 8 hours post freeze suggesting the activation of a delayed mitochondrial cell death signaling response.

**Figure 4:** Assessment of the impact of caspase inhibition on C2 survival following freezing. Samples were treated for 30 mins with pan caspase inhibitor and then exposed to a 5 minute freeze to −10°C, −15°C, or −20°C. Caspase inhibition in samples exposed to −15°C resulted in an increase in cell survival compared to non-inhibited −15°C samples, indicating apoptosis may play a significant role in C2 death following freezing.

of -25°C and lower were achieved regardless of the hold time. The data also demonstrate that when temperatures ≥-20°C were applied the exposure time (hold time) was an important factor. The impact of freezing to <-20°C was confirmed in both the in vitro cell model and pilot ex vivo MCT tissue evaluations. These data correlate well with previous reports from our laboratory on CA in cell systems such as prostate and renal cancer [39,52], establishing that both the nadir temperature and time at temperature play a role in overall outcome.

When performing solid tumor cryosurgery, the temperature typically reached at the center of a cryogenic lesion ranges between -80°C and -180°C [11,47,50,51]. Extending radially from the center of the cryolesion, temperatures increase until the edge of the frozen mass, where temperatures are 0°C, nominally (Figure 6). The corresponding isothermal gradient (temperature gradient profile) within the frozen mass varies depending on application time, freeze repetition, and cryogen utilized [11,47,50,51]. As such, it is important to understand the characteristics of the cancer cell response to the range of temperatures associated with a cryogenic lesion. Our studies focused on the warmer sub-freezing temperatures associated with the periphery (outer edge) of the freeze lesion, as it is generally accepted that temperatures below -40°C result in complete cancer cell lysis through physical ice rupture [12,13]. The thermal range of 0°C to -40°C is characterized by a region of heterogenic cell responses which includes cell lysis, activation of necrotic and apoptotic pathways, as well as some cell survival [11,39,45]. Numerous reports by our group as well as others have demonstrated the transition from complete cell death to complete cell survival within this region [39,53,54,43]. Given these facts, it is important to identify the critical lethal temperature for MCT cells as well as understand the molecular responses of this cancer to CA to yield more effective treatment. To this end, the data revealed the minimal lethal temperature for C2 MCT cells was -25°C in vitro whereas the -15°C to -20°C range resulted in a heterogeneous mix of necrotic, apoptotic and surviving cell populations. The data also demonstrated that regardless of the exposure temperature, necrosis was the primary mode of cell death. Apoptotic contribution to cell death following freezing has been reported primarily at warmer, sub-freezing temperatures [43,55-57]. In this study, apoptotic involvement was found following exposure to -15°C and was most prominent at 1 and 8 hours post-freeze resulting in the delayed cell death response.

Proteomic analysis confirmed the contribution of a delayed molecular response. The observed loss of Bcl-2 and maintenance of Bax total protein levels (western blot analysis) suggested a shift in the Bcl-2/Bax ratio, thus indicating the activation of the mitochondrial molecular switch signaling the initiation of apoptosis. This is consistent with Robilotto, et al., [55], wherein it was reported that exposure of prostate cancer cells to -15°C results in the activation of mitochondrial based apoptosis whereas exposure to temperatures of ≤-30°C results in the initiation of membrane mediated apoptosis. The observed decrease in pAkt following freezing further suggests
that the loss of pro-survival signaling contributes significantly to the overall level of cell death. Combined with the observed increases in PARP cleavage and Caspase activation, the molecular data suggest that multiple cell death pathways are involved in low temperature death responses in mast cells.

Given that the incidence of MCT’s is largely breed specific, a genetic basis for tumor development is likely. Numerous studies have implicated the c-kit gene product, an integral membrane receptor tyrosine kinase (RTK), in MCT signaling [58–61]. Many mutations in this gene cause the constitutively active form of the receptor, signaling the cell to proliferate even in the absence of its ligand, stem cell factor [58]. As such, c-kit specific small molecule inhibitors have been used with some success. Drug resistance, however, could become an issue in vivo [60]. Previous studies from our laboratory have shown the success of adjuvants used for cryosensitization [37,57,62–65]. These and other studies have detailed the benefit of adjunctive treatment involving CA with the pre-treatment of low-dose chemotherapy, nutraceuticals or other agents in a number of cancers including prostate, breast, lung and liver among others [37,65–77]. In vitro and in vivo studies involving prostate cancer have shown the ability of cryosensitizing adjuvants to elevate the minimal lethal temperature for hormone refractory prostate cancer from -40°C to -20°C via pre-treatment with sub-clinical (non-toxic) doses of 5-fluorocil, taxotere and cisplatin [65,66,71]. Other studies have demonstrated that combinatorial approaches using the active nutraceutical calcitriol (vitamin D3) can result in the elevation of the minimal lethal temperature for hormone refractory prostate cancer from -40°C to -20°C via pre-treatment with sub-clinical (non-toxic) doses of 5-fluorocil, taxotere and cisplatin [65,66,71].

In conclusion, the data from this study suggest that CA has the potential to be an effective therapeutic option for the treatment of canine mast cell tumors, both malignant and benign. The findings provide a baseline characterization of the cellular and molecular responses of an MCT cell line to freezing as well as identified -20°C to -25°C as the critical temperature range for complete MCT cell destruction depending on hold time. Complete C2 cell destruction at -25°C was found regardless of the hold time whereas a hold of 10 minutes was necessary of complete destruction at -20°C. Pilot study ex vivo freezing of grade 2, stage 2 MCT tissue correlated with in vitro findings and in combination provide a basis for the further exploration of the use of CA for the treatment of MCT in vivo. The data presented herein suggest that CA may provide a minimally invasive, rapid therapeutic option for treating mast cell tumors. As such, additional studies in the application of CA for MCT treatment are warranted.

Acknowledgement

The authors would like to acknowledge Dr. Alison Beaulieu, DVM, for the surgical removal and staging of MCT tissue, as well as her continued interest and support in our research efforts. The authors would also like to thank Mr. Jordan M. Katz for his contributions to data acquisition for this manuscript.

Declarations

Funding: This study was supported in part by funding from the National Institutes of Health 1R43CA183265–01 awarded to CPSI Biotech.

Conflicts of interests: JMB, KKS, KLS and RVB are employees of CPSI Biotech. JGB has no competing interests.

Authors’ contributions: KLS, JMB and KKS performed all experimental design, experimentation and data analysis for this study. RVB and JGB conducted data and experimental design review and assisted in data interpretation. JMB and KLS prepared the draft manuscript. JMB, KLS, KKS, RVB and JGB provided review and revision input for the manuscript. All authors read and approved the final manuscript.

Availability of data and material: The data that support the findings of this study are available from CPSI Biotech but restrictions apply to the availability of these data, which were under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of CPSI Biotech.

References


Copyright: © 2020 Santucci KL, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.